

Press Release

February 2, 2026

Announcement of Organizational Changes and Personnel Changes

Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, CEO: Akihisa Harada) announced today the following organizational changes and personnel changes.

■ Organizational Changes (Effective as of April 1, 2026)

- The Corporate Strategy Division will be renamed to the “Corporate Operations Division”.
- The Legal, Compliance, and Intellectual Property Division will be abolished. Subordinate departments will report directly to the Chief Transformation Officer & General Counsel.
- The Business Development Division will be abolished, and the subordinate departments will be transferred to the Corporate Operations Division.
- The Finance Division will be abolished. Subordinate departments will report directly to the Chief Financial Officer.
- The Human Resources & General Affairs Division will be abolished. Subordinate departments will report directly to the Chief Human Resources Officer. An executive officer in charge of “Reform Projects” will be newly established under the Chief Human Resources Officer.
- The Global Development & Medical Affairs Division will be renamed “US Development” and the Development & Medical Affairs Division will be renamed “Development Division”. An executive officer “Head of Regulatory Affairs” will be newly established to report to the Head of Development Division.
- The Japan Pharmaceutical Business Division will be reorganized into the “Marketing Division” and the “Sales Division”.

■ Personnel Changes (Effective as of April 1, 2026)

• Appointment

New	Name	Current
Executive Officer, Head of Marketing Div.	Kiyonobu Kawano※	Japan Pharmaceutical Business Div.
Executive Officer, Head of Sales Div.	Hajime Minami	Senior Vice President, Japan Pharmaceutical Business Div.

※ Joined February 1, 2026

• Change of assigned duties

New	Name	Current
Chief Transformation Officer & General Counsel	Kazumasa Nagayama	Chief Transformation Officer & General Counsel, Head of Business Development Div.


Chief Financial Officer	Amit Singh	Chief Financial Officer, Head of Finance Div.
Chief R&D Officer	Masahiko Ohtsuki	Chief Scientific Officer
Executive Officer, Head of Corporate Operations Div.	Tetsuro Iwata	Executive Officer, Head of Corporate Strategy Div.
Executive Officer, Head of US Development	Bijan Nejadnik	Chief Medical Officer, Head of Global R&D, and Global Development & Medical Affairs Div.
Executive Officer, Head of Development Div.	Kazuhiro Kanmuri	Executive Officer, Special Assignment to the CEO
Executive Officer, in Charge of Reform Project	Tomoaki Tokuno	Executive Officer, Head of Human Resources & General Affairs Div.
Executive Officer, Head of Regulatory Affairs	Yousuke Kimura	Executive Officer, Head of Development & Medical Affairs Div.

■ Directors of the Board and Executive Team (Effective as of April 1, 2026)

Title	Name
Representative Director of the Board, Chief Executive Officer	Akihisa Harada
President, Representative Director of the Board, Chief Operating Officer	Akihiro Tsujimura
Chairman, Director of the Board	Costa Saroukos
Director of the Board	Ryousuke Tanabe
Director of the Board	Yuji Sugimoto
Director of the Board	Masashi Suekane
Director of the Board	Hiroki Inada
Director of the Board	William Cozean
Director of the Board	Nicholas Gattas
Corporate Auditor	Satomi Takada

Corporate Auditor	Shintaro Kohmoto
Chief Transformation Officer & General Counsel	Kazumasa Nagayama
Chief Business Officer	Sean Ryan
Chief Financial Officer	Amit Singh
Chief Human Resources Officer	Naoki Ohta
Chief Information Officer, Head of IT Digital Div.	Keitaro Shigemasa
Chief R&D Officer	Masahiko Ohtsuki
Executive Officer, Head of Corporate Operations Div.	Tetsuro Iwata
Executive Officer, Head of Research Div.	Naoya Masutomi
Executive Officer, Head of US Development	Bijan Nejadnik
Executive Officer, Head of Development Div.	Kazuhiro Kanmuri
Executive Officer, Head of Product Supply Div.	Kenji Taguchi
Executive Officer, Head of Quality & Vigilance Div.	Masanobu Kono
Executive Officer, Head of Marketing Div.	Kiyonobu Kawano
Executive Officer, Head of Sales Div.	Hajime Minami
Executive Officer, Head of North America Business Div.	Yasutoshi Kawakami
Executive Officer, Head of Asia and Europe Business Div.	Toshifumi Tada
Executive Officer, Head of Market Access and External Affairs	Simon Collier
Executive Officer, in Charge of Reform Project	Tomoaki Tokuno
Executive Officer, Head of Regulatory Affairs	Yousuke Kimura

■ Management Structure Chart (Effective as of April 1, 2026)



Contact:
Tanabe Pharma Corporation
CEO Office PR Group
+81-6-6205-5119